The projected decrease in operating expenses for ReShape Lifesciences is a positive indicator of the company's ability to manage costs and improve operational efficiency. This significant reduction is likely to be viewed favorably by investors, as it suggests potential for improved profitability and financial health in the near term. The direct mention of RSLS and the specific figure of a 55.4% reduction make this news highly relevant and important for investors in RSLS, leading to a positive score.